The patient journey toward a diagnosis of hereditary transthyretin (ATTRv) amyloidosis
Abstract Background Despite emerging treatments for hereditary transthyretin (ATTRv) amyloidosis, the disease is often misdiagnosed, with reported diagnostic delays of up to several years. Knowledge of the patient journey leading up to diagnosis may help to promote earlier intervention. The study’s...
Main Authors: | Montserrat Vera-Llonch, Sheila R. Reddy, Eunice Chang, Marian H. Tarbox, Michael Pollock |
---|---|
Format: | Article |
Language: | English |
Published: |
BMC
2021-01-01
|
Series: | Orphanet Journal of Rare Diseases |
Subjects: | |
Online Access: | https://doi.org/10.1186/s13023-020-01623-1 |
Similar Items
-
The Clinical and Economic Burden of Newly Diagnosed Hereditary Transthyretin (ATTRv) Amyloidosis: A Retrospective Analysis of Claims Data
by: Sheila R. Reddy, et al.
Published: (2020-05-01) -
Urinary Transthyretin as a Biomarker in ATTRv Val50Met Amyloidosis
by: Hiroaki Matsushita, et al.
Published: (2022-06-01) -
Hereditary transthyretin amyloidosis: a case report
by: Angela Lee, et al.
Published: (2022-06-01) -
Healthcare resource use associated with the diagnosis of transthyretin amyloidosis cardiomyopathy
by: Clint Asher, et al.
Published: (2022-01-01) -
The impact of inotersen on Neuropathy Impairment Score in patients with hereditary transthyretin amyloidosis with polyneuropathy
by: Aaron Yarlas, et al.
Published: (2023-03-01)